journal article·2021-05-05

Biocompatible Ionic Liquid-Mediated Micelles for Enhanced Transdermal Delivery of Paclitaxel

Md. Korban Ali, Rahman Md Moshikur, Rie Wakabayashi, Muhammad Moniruzzaman, Masahiro Goto

ACS Applied Materials & Interfaces· Volume 13· Issue 17
Publisher page

Abstract

Chemotherapeutic cytotoxic agents such as paclitaxel (PTX) are considered essential for the treatment of various cancers. However, PTX injection is associated with severe systemic side effects and high rates of patient noncompliance. Micelle formulations (MFs) are nano-drug delivery systems that offer a solution to these problems. Herein, we report an advantageous carrier for the transdermal delivery of PTX comprising a new MF that consists of two biocompatible surfactants: cholinium oleate ([Cho][Ole]), which is a surface-active ionic liquid (SAIL), and sorbitan monolaurate (Span-20). A solubility assessment confirmed that PTX was readily solubilized in the SAIL-based micelles via multipoint hydrogen bonding and cation−π and π–π interactions between PTX and SAIL[Cho][Ole]. Dynamic light scattering (DLS) and transmission electron microscopy revealed that in the presence of PTX, the MF formed spherical PTX-loaded micelles that were well-distributed in the range 8.7–25.3 nm. According to DLS, the sizes and size distributions of the micelle droplets did not change significantly over the entire storage period, attesting to their physical stability. In vitro transdermal assessments using a Franz diffusion cell revealed that the MF absorbed PTX 4 times more effectively than a Tween 80-based formulation and 6 times more effectively than an ethanol-based formulation. In vitro and in vivo skin irritation tests revealed that the new carrier had a negligible toxicity profile compared with a conventional ionic liquid-based carrier. Based on these findings, we believe that the SAIL[Cho][Ole]-based MF has potential as a biocompatible nanocarrier for the effective transdermal delivery of poorly soluble chemotherapeutics such as PTX.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advanced Drug Delivery Systems · Advancements in Transdermal Drug Delivery · Surfactants and Colloidal Systems

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Applied Chemistry, Graduate School of Engineering, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819-0395, Japan

Department of Chemistry, Jashore University of Science and Technology, Jashore 7408, Bangladesh

Advanced Transdermal Drug Delivery System Center, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819-0395, Japan

Chemical Engineering Department, Universiti Teknologi PETRONAS, Seri Iskandar, 32610 Perak, Malaysia

Division of Biotechnology, Center for Future Chemistry, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819-0395, Japan

Funding

Ministry of Education, Culture, Sports, Science and Technology · Japan Society for the Promotion of Science

References (68)

Show source-provided references
1. 10.1111/j.2042-7158.2010.01184.x10.1111/j.2042-7158.2010.01184.x ↗
2. 10.1016/S0378-5173(01)00986-310.1016/S0378-5173(01)00986-3 ↗
3. 10.1021/am505308f10.1021/am505308f ↗
4. 10.1021/acsami.6b0807910.1021/acsami.6b08079 ↗
5. 10.1021/acs.molpharmaceut.8b0030510.1021/acs.molpharmaceut.8b00305 ↗
6. 10.1016/j.ijbiomac.2020.01.09410.1016/j.ijbiomac.2020.01.094 ↗
7. 10.1016/j.ijpharm.2018.03.03010.1016/j.ijpharm.2018.03.030 ↗
8. 10.1021/acsami.8b0812510.1021/acsami.8b08125 ↗
9. 10.1016/j.farmac.2005.07.00410.1016/j.farmac.2005.07.004 ↗
10. 10.1021/am507798d10.1021/am507798d ↗
11. 10.1016/j.ijpharm.2020.11941210.1016/j.ijpharm.2020.119412 ↗
12. 10.1016/j.msec.2020.11104610.1016/j.msec.2020.111046 ↗
13. 10.5402/2012/62313910.5402/2012/623139 ↗
14. 10.1016/j.ejpb.2011.04.01710.1016/j.ejpb.2011.04.017 ↗
15. 10.1021/am504051b10.1021/am504051b ↗
16. 10.1021/am403992b10.1021/am403992b ↗
17. 10.1021/am506872310.1021/am5068723 ↗
18. 10.1021/acsami.0c0410210.1021/acsami.0c04102 ↗
19. 10.1021/acsami.9b1615010.1021/acsami.9b16150 ↗
20. 10.1039/c7nr05935c10.1039/c7nr05935c ↗
21. 10.1021/jp403265p10.1021/jp403265p ↗
22. 10.1021/acssuschemeng.9b0777310.1021/acssuschemeng.9b07773 ↗
23. 10.1080/10837450.2020.180390910.1080/10837450.2020.1803909 ↗
24. 10.2174/092986732566618102611022710.2174/0929867325666181026110227 ↗
25. 10.2174/258997751166619112510333810.2174/2589977511666191125103338 ↗
26. 10.1021/am405745310.1021/am4057453 ↗
27. 10.1039/d0gc02387f10.1039/d0gc02387f ↗
28. 10.1016/j.ijpharm.2012.10.03510.1016/j.ijpharm.2012.10.035 ↗
29. 10.1016/j.ijpharm.2016.11.02010.1016/j.ijpharm.2016.11.020 ↗
30. 10.1016/j.molliq.2016.11.13610.1016/j.molliq.2016.11.136 ↗
31. 10.1016/j.molliq.2019.11216610.1016/j.molliq.2019.112166 ↗
32. 10.1016/j.ijpharm.2010.08.03410.1016/j.ijpharm.2010.08.034 ↗
33. 10.1021/acsami.5b0440510.1021/acsami.5b04405 ↗
34. Mehta D. · Int. J. Pharm. Sci. · 2015 · 1 · 48
35. 10.1016/j.ijpharm.2017.10.02410.1016/j.ijpharm.2017.10.024 ↗
36. 10.1016/j.ijpharm.2018.05.02110.1016/j.ijpharm.2018.05.021 ↗
37. 10.1016/j.ijpharm.2017.10.02410.1016/j.ijpharm.2017.10.024 ↗
38. 10.1016/j.jcis.2010.08.03510.1016/j.jcis.2010.08.035 ↗
39. 10.1016/j.ijpharm.2019.01.02110.1016/j.ijpharm.2019.01.021 ↗
40. 10.1016/j.jcis.2014.11.04410.1016/j.jcis.2014.11.044 ↗
41. 10.1039/c5md00168d10.1039/c5md00168d ↗
42. 10.2131/jts.34.32710.2131/jts.34.327 ↗
43. 10.3109/03639045.2016.115102810.3109/03639045.2016.1151028 ↗
44. 10.1016/j.jcis.2019.04.09510.1016/j.jcis.2019.04.095 ↗
45. 10.1016/j.molliq.2020.11442410.1016/j.molliq.2020.114424 ↗
46. 10.1021/la502312n10.1021/la502312n ↗
47. 10.1080/01932691.2018.148928010.1080/01932691.2018.1489280 ↗
48. 10.1002/jsde.1218110.1002/jsde.12181 ↗
49. 10.4155/fmc-2018-058010.4155/fmc-2018-0580 ↗
50. 10.1002/pi.262910.1002/pi.2629 ↗
51. 10.1016/j.molliq.2019.01.06310.1016/j.molliq.2019.01.063 ↗
52. 10.1016/j.ijpharm.2018.12.02510.1016/j.ijpharm.2018.12.025 ↗
53. 10.1021/acsami.7b1668610.1021/acsami.7b16686 ↗
54. 10.1021/la901498e10.1021/la901498e ↗
55. 10.1021/jp109088h10.1021/jp109088h ↗
56. 10.1021/la303193n10.1021/la303193n ↗
57. 10.1021/acssuschemeng.0c0341910.1021/acssuschemeng.0c03419 ↗
58. 10.1021/jp310616p10.1021/jp310616p ↗
59. 10.1016/j.bfopcu.2013.07.00210.1016/j.bfopcu.2013.07.002 ↗
60. 10.1039/b907462g10.1039/b907462g ↗
61. 10.1016/j.molliq.2019.11134710.1016/j.molliq.2019.111347 ↗
62. 10.1016/j.molliq.2017.11.04410.1016/j.molliq.2017.11.044 ↗
63. 10.3390/pharmaceutics1204039210.3390/pharmaceutics12040392 ↗
64. 10.1016/j.jconrel.2003.11.00410.1016/j.jconrel.2003.11.004 ↗
65. 10.1039/b711119c10.1039/b711119c ↗
66. 10.1016/j.ijpharm.2019.05.02010.1016/j.ijpharm.2019.05.020 ↗
67. 10.1021/acs.molpharmaceut.0c0021110.1021/acs.molpharmaceut.0c00211 ↗
68. 10.1021/am507800e10.1021/am507800e ↗